^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Yinuokai (orelabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prospective, multicenter phase II clinical study of orelabrutinib combined with immunochemotherapy in the treatment of newly treated high-risk diffuse large B-cell lymphoma
Excerpt:
...One of the following conditions must be met to be included in the study: (1) The longest diameter of the mass assessed by CT or PET/CT is >=10 cm; (2) International Prognostic Index (IPI) >= 2 points; (3) There are more than 2 extranodal lesions; (4) Involvement of the central nervous system; (5) Secondary to the second tumor or combined with the second tumor; (6) Genetic abnormalities or molecular biological abnormalities with known poor prognosis, such as P53 gene mutation, MYD88/CD79B mutation, c-MYC/BCL2 double expression, c-MYC/BCL-2/BCL-6 double strike or triple strike; (7) CNS-IPI score >= 2 points; 5. ...
Trial ID:
Source:
Title:
ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
Published date:
06/09/2023
Excerpt:
We aimed to analyze efficacy and safety of O plus R-CHOP-like (O+R-CHOP) for untreated non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) patients (pts)...5, 2, and 1 pt had detected MYD88, CD79A, and TP53 mutations, respectively....By subgroup analysis of 11 pts after induction stage...pts with MYD88 and CD79A mutations obtained CR of 80.0% and 100.0%, respectively among 10 pts with O+R-CHOP.
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.1002/hon.3165_659
Trial ID:
